Rhythm's Setmelanotide Data And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 06/28/20
Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese VolunteersGlobeNewsWire • 06/24/20
Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency ObesitiesGlobeNewsWire • 05/13/20
Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business OperationsGlobeNewsWire • 03/30/20
Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency ObesitiesGlobeNewsWire • 03/30/20
Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström SyndromeGlobeNewsWire • 03/18/20
Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström SyndromesGlobeNewsWire • 12/05/19
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 10/18/19
Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders GlobeNewsWire • 09/09/19
Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in SeptemberGlobeNewsWire • 09/03/19